Moderna Exec Says Co Could Consider Partnerships And Project Financing As Options To Fund Pipeline Programs Beyond 2026
Moderna Exec Says Co Could Consider Partnerships And Project Financing As Options To Fund Pipeline Programs Beyond 2026.
Health Care
“Moderna Rises On New Skin Cancer Treatment Trial With Merck, Analysts Say” – Reuters
Oppenheimer analyst Hartaj Singh cites Moderna’s share move to a notice on the U.S. clinical trials register that the company, along with Merck MRK.N, will begin testing their vaccine combination for the treatment of a form of skin cancer called cutaneous squamous cell carcinoma (CSCC) CSCC is the second-most common form of skin cancer in the U.S. Merck’s immunotherapy Keytruda along with Moderna’s MRNA-based vaccine are also being evaluated for the treatment of melanoma and non-small cell lung cancer Analysts at Jefferies say this being the third late-stage study for the vaccine combination speaks to continued confidence in a broad program
“Moderna Rises On New Skin Cancer Treatment Trial With Merck, Analysts Say” – Reuters Read Post »
UnitedHealth’s Stock Can Soar 40% as Antitrust Concerns Are Overblown, BofA Says
By Tomi Kilgore Justice Department antitrust probe and recent cyberattack were bad news for UnitedHealth – but not as bad as stock’s selloff suggests, analyst says Shares of UnitedHealth Group Inc. rallied Thursday after a ringing endorsement from BofA Securities analyst Kevin Fischbeck, who said investor concerns about an antitrust investigation and a recent cyberattack are way overblown. Fischbeck reiterated his buy rating on the health insurer’s stock (UNH), which he said is now his “top pick.” His $675 price target – which makes Fischbeck the most bullish of the 28 analysts surveyed by FactSet who cover UnitedHealth – implies roughly 41% upside from current levels. The stock rose 0.9% in afternoon trading, after closing Wednesday at its lowest price since July 13, 2023. The bounce comes after UnitedHealth shares tumbled 10.4% amid an eight-session losing streak, which was their longest such streak since an eight-day stretch that ended March
UnitedHealth’s Stock Can Soar 40% as Antitrust Concerns Are Overblown, BofA Says Read Post »
CFRA Maintains Hold Opinion On Shares Of Unitedhealth Group Incorporated
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our 12-month target by $54 to $517, an 18.6x multiple of our 2024 EPS estimate (down by $0.05 to $27.80; we cut our 2025 estimate by $0.13 to $31.36), a premium to managed health care peers but below UNH’s historical average. A significant cyberattack on UNH’s Change Healthcare business (part of Optum) on February 21 continues to disrupt pharmacies, payments, and claims nationwide. Positively, UNH sees 90% of medical claims uninterrupted and expects to reach 95% next week. UNH also views pharmacy claims near normal volume. HHS released guidance from CMS encouraging workarounds such as removing prior authorizations and using alternative electronic data interchanges (EDI). We have seen shares other health care names like HCA Healthcare (HCA 323 ***) and Henry Schein (HSIC 76 ***)
CFRA Maintains Hold Opinion On Shares Of Unitedhealth Group Incorporated Read Post »
Barclays analyst initiates coverage on UnitedHealth Group (NYSE:UNH) with a Overweight
Barclays analyst Andrew Mok initiates coverage on UnitedHealth Group (NYSE:UNH) with a Overweight rating and announces Price Target of $551.
Barclays analyst initiates coverage on UnitedHealth Group (NYSE:UNH) with a Overweight Read Post »
CFRA Adds Eli Lilly To The High-quality Capital Appreciation Portfolio
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We add Eli Lily and Company (LLY) to CFRA’s High-Quality Capital Appreciation Portfolio. LLY is one of the largest U.S. drug makers in terms of revenue and is a leading developer of drugs in a wide range of therapeutic areas such as endocrinology, which includes a diabetes drug portfolio that generates more than half of its total revenue. We are increasingly optimistic on LLY’s many ongoing efforts, including late-stage therapies such as donanemab (for Alzheimer’s disease), pirtobrutinib (for certain forms of leukemia and lymphoma), and tirzepatide (for sleep apnea and cardiology). Such innovation could complement LLY’s 10 key current drugs, which represent the majority of LLY’s total sales. LLY replaces CVS Health Corporation, which was downgraded to a Hold recommendation.
CFRA Adds Eli Lilly To The High-quality Capital Appreciation Portfolio Read Post »
CFRA Retains Strong Buy Opinion On Shares Of Eli Lilly And Company
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $56 to $885, reflecting 57.0x our 2025 EPS, justified by LLY’s robust revenue and earnings growth outlook. We lift our 2024 EPS estimate by $0.10 to $12.50 and our 2025 view by $0.06 to $15.53. Leaving behind a year of robust performance in 2023 with top-line revenue growth of 28% Y/Y, we think LLY will continue to outperform peers. We see superior growth prospects for Eli Lilly in the next two years in an environment where competitors will see slower growth and more limited cushion against key drugs’ loss of exclusivities. We updated our model and now expect 2024 revenue growth of 21% Y/Y and another 14% Y/Y in 2025, while we expect record EPS growth of 98% Y/Y and 24%
CFRA Retains Strong Buy Opinion On Shares Of Eli Lilly And Company Read Post »
Cantor Fitzgerald analyst reiterates Pfizer (NYSE:PFE) with a Overweight
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Cantor Fitzgerald analyst reiterates Pfizer (NYSE:PFE) with a Overweight Read Post »
RBC Capital analyst reiterates UnitedHealth Group with a Outperform
RBC Capital analyst Ben Hendrix reiterates UnitedHealth Group with a Outperform and maintains $596 price target.
RBC Capital analyst reiterates UnitedHealth Group with a Outperform Read Post »
Amgen’s Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs
Amgen Inc (NASDAQ:AMGN) is expected to unveil updates on various programs this year, targeting significant markets. Despite concerns about the company’s long-term growth amid exclusivity losses, Goldman Sachs notes that Amgen (Buy rating, $350 price target) is seen as well-positioned to capitalize on multi-billion dollar opportunities. The current stock valuation is slightly above the base business, per the discounted cash flow model, and indicates a favorable risk-reward scenario leading up to upcoming catalysts. The upcoming catalysts include obesity, with MariTide Phase 2 data expected in late 2024. Earlier this month, Amgen had the data from animal and early-stage human trials of its experimental obesity drug AMG 133 (maridebart cafraglutide) published in Nature Metabolism. The Journal confirmed the GIPR antagonist and GLP-1R agonist activities in cell-based systems and reported the ability of AMG 133 to reduce body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. The management has
Pfizer (NYSE:PFE) Stock Analyst Ratings
Pfizer (NYSE:PFE) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/23/2024 30.03% Guggenheim → $36 Initiates Coverage On → Buy 01/31/2024 62.54% Cantor Fitzgerald → $45 Reiterates Overweight → Overweight 01/09/2024 62.54% Cantor Fitzgerald → $45 Reiterates Overweight → Overweight 01/04/2024 15.59% TD Cowen → $32 Downgrades Outperform → Market Perform 12/14/2023 30.03% Truist Securities $42 → $36 Maintains Buy 12/14/2023 -2.47% UBS $34 → $27 Maintains Neutral 12/14/2023 1.14% Barclays $34 → $28 Maintains Equal-Weight 12/04/2023 51.71% Truist Securities → $42 Reiterates Buy → Buy 11/20/2023 170.9% Cantor Fitzgerald → $75 Reiterates Overweight → Overweight 11/01/2023 22.81% Barclays $35 → $34 Maintains Equal-Weight 11/01/2023 33.65% Morgan Stanley $39 → $37 Maintains Equal-Weight 10/20/2023 22.81% UBS $36 → $34 Assumes Neutral → Neutral 10/17/2023 51.71% Truist Securities $62 → $42 Maintains Buy 10/17/2023 40.87% Morgan Stanley $40 → $39 Maintains Equal-Weight 10/17/2023
Pfizer (NYSE:PFE) Stock Analyst Ratings Read Post »
Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings
Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/20/2024 7.73% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/16/2024 25.58% Morgan Stanley $805 → $950 Maintains Overweight 02/14/2024 7.73% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/07/2024 12.36% Truist Securities $650 → $850 Maintains Buy 02/07/2024 6.41% Morgan Stanley $763 → $805 Maintains Overweight 02/07/2024 7.07% Barclays $680 → $810 Maintains Overweight 02/07/2024 9.05% Wells Fargo $700 → $825 Maintains Overweight 02/07/2024 14.34% BMO Capital $710 → $865 Maintains Outperform 02/06/2024 9.05% Wells Fargo $700 → $825 Maintains Overweight 02/06/2024 7.73% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -16.72% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -16.72% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -7.47% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -16.72% Cantor Fitzgerald → $630 Reiterates Overweight →
Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Read Post »